This is the question almost everyone arrives with, and the honest answer is that nobody knows the date yet. What can be said precisely is what has already happened, what still has to happen, and why the gap between a regulator saying yes and a pharmacy being able to dispense something is longer than most coverage implies.
What has happened so far
On 10 August 2026 the Medicines and Healthcare products Regulatory Agency authorised orforglipron, which Eli Lilly sell as Foundayo, for weight management and for blood sugar control in type 2 diabetes. The UK is the first country in Europe to do so. That decision means the regulator has assessed the medicine's safety, quality and effectiveness and concluded it can be marketed here. It is a significant milestone and it is frequently reported as though it were the finish line. It is not.
The four steps people run together
Getting a medicine from authorisation into someone's hands involves several distinct stages, each with its own timetable. Authorisation is the regulator's decision that the medicine may be sold. Launch is the manufacturer's decision about when to bring it to a particular market, which depends on manufacturing capacity, packaging in UK-specific formats, distribution agreements and commercial planning. Supply is whether there is enough of it, which for GLP-1 medicines has repeatedly been the binding constraint rather than an afterthought. And NHS funding is a separate assessment altogether, run by NICE, about whether the health service should pay for it. A medicine can be authorised and still be months away on every one of the other three.
What a realistic estimate looks like
Based on how previous GLP-1 authorisations have translated into availability, late 2026 to early 2027 is a reasonable expectation for private prescribing, and that is the range most commentary has settled on. It should be treated as an informed guess rather than a plan. Eli Lilly have not announced a UK launch date. Recent history with this class of medicine also counsels caution: demand for GLP-1 treatments has repeatedly outstripped supply, and manufacturers have staged launches and restricted new starts to protect continuity for existing patients. A launch that is technically announced but effectively rationed is a realistic scenario.
The NHS timetable is the one firm date
The National Institute for Health and Care Excellence is appraising orforglipron for managing overweight and obesity, and guidance is due to be published on 18 November 2026. That appraisal weighs clinical and cost effectiveness within the terms of the authorisation, and it determines whether the NHS will fund the medicine and, if so, for whom. Even a positive recommendation would not mean immediate broad access. NHS weight-management services have limited capacity and existing GLP-1 treatments are already rationed through specialist pathways, so eligibility on paper and an appointment in practice remain some distance apart.
Why private availability usually comes first
With every recent weight-management medicine, private prescribing has preceded NHS access by a considerable margin, because a private route needs only the product to exist and a prescriber to assess suitability, whereas NHS access needs a funding decision and service capacity. There is no reason to expect a different pattern here. That said, private availability still depends entirely on the manufacturer supplying the UK market, which is the step nobody outside Eli Lilly can currently forecast.
Supply is the constraint that catches people out
Of the four steps, supply is the one that has repeatedly proved decisive for this class of medicine and the one least often discussed. When the injectable GLP-1 treatments became widely known, demand rose faster than manufacturing capacity, and the consequence was months of disrupted availability: some strengths unobtainable, pharmacies unable to fill repeat prescriptions, and prescribers advised to prioritise continuity for existing patients over starting new ones. Orforglipron has a structural advantage here, because a small-molecule tablet is more straightforward to manufacture at scale than a peptide requiring sterile injection devices, and that is a genuine reason to expect supply to keep up better than it did previously. It is not a guarantee, and the interest generated by being first in Europe will not make the early months easier.
What to do while waiting
If you are considering weight-management treatment and meet the criteria, the practical option is an assessment against what is available now rather than a wait of unknown length. The authorised thresholds are the same across these medicines, so an assessment done today remains relevant later. There is also a reasonable argument for starting treatment that is available and switching later if orforglipron turns out to suit you better, rather than deferring: the treatments already licensed produced larger average weight loss in trials, so waiting is not obviously trading down. What is worth avoiding is putting money or personal details into any site promising early access, a preorder or a place in a queue.
How you will know when it happens
A genuine UK launch will be visible in ordinary places: the medicine will appear in the electronic medicines compendium with a UK summary of product characteristics, it will be listed in the British National Formulary, and registered pharmacies will be able to dispense it against a prescription. NICE will publish its appraisal on its own site. If none of those exist and a website is nonetheless selling the product, that tells you what you need to know. Our Health Hub coverage will be updated as the position changes, and the sensible approach in the meantime is patience rather than a preorder.
